US-based pharmaceutical firm Pfizer has suffered a significant blow on the hunt to have its once-weekly growth hormone, somatrogon, approved for the US market.
In a press release, Pfizer announces that it has received a so-called ”complete response letter” from the US Food and Drug Administration (FDA), entailing the agency’s rejection of the would-be treatment of growth hormone deficiency (GHD) for pediatric patients.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.